Ponesimod is a novel, effective, selective S1P1 receptor agonist. Ponesimod binds to the S1P1 receptor, causing receptor internalisation, thereby inhibiting the outflow of lymphocytes from lymph nodes. This action reduces the number of lymphocytes in the blood and limits their arrival at sites of inflammation, helping to slow the progression of multiple sclerosis.
